Stock Price
80.20
Daily Change
1.78 2.27%
Monthly
6.78%
Yearly
40.46%
Q1 Forecast
69.50

Halozyme Therapeutics reported $1.72 in EPS Earnings Per Share for its fiscal quarter ending in September of 2025.


Fiscal Calendar Actual Consensus Previous Date
FY2025Q4 Dec/2025 1.9 1.26 Feb/24 2026
FY2025Q3 Sep/2025 1.72 1.59 1.27 Nov/03 2025
FY2025Q2 Jun/2025 1.54 1.21 0.91 Aug/05 2025
FY2025Q1 Mar/2025 1.11 0.96 0.79 May/06 2025
FY2024Q4 Dec/2024 1.26 1.15 0.82 Feb/18 2025




Eps Change Date
Acadia Pharmaceuticals USD 0.42 0.26 Sep/2025
Agios Pharmaceuticals USD -1.78 0.15 Sep/2025
Alnylam Pharmaceuticals USD 2.9 2.58 Sep/2025
Amarin USD 0.08 0.11 Sep/2025
Amgen USD 5.29 0.35 Dec/2025
Baxter International USD 0.69 0.1 Sep/2025
Cytokinetics USD -2.55 1.43 Sep/2025
DBV Technologies USD -0.24 1.31 Sep/2025
Eli Lilly USD 7.54 0.52 Dec/2025
Halozyme Therapeutics USD 1.72 0.18 Sep/2025
Ionis Pharmaceuticals USD -0.8 1.5 Sep/2025
MannKind USD 0.07 0.02 Sep/2025
Pfizer USD 0.66 0.21 Dec/2025
United Therapeutics USD 7.16 0.75 Sep/2025